-
Health todayObesity, diabetes and GLP-1 refines
Lower systolic target in type 2 diabetes did not cut dementia or mild cognitive impairment
A systolic target below 120 mm Hg did not reduce dementia or mild cognitive impairment in type 2 diabetes.
Peer-reviewed -
Health todayHeart and stroke refines
Carotid atherosclerosis linked to dementia risk in a meta-analysis of 97 studies
Thicker carotid walls and asymptomatic stenosis were linked to dementia risk, but larger trials found no cognitive benefit from revascularisation.
Preprint · not peer-reviewed -
Health todayDementia refines
Brain-derived plasma p-tau217% outperforms standard p-tau217 for Alzheimer's pathology
Brain-derived plasma p-tau217% separated low from severe Alzheimer's neuropathological change with an AUC of 0.93, against 0.90 for standard p-tau217.
Preprint · not peer-reviewed -
Health todayDementia refines
Repeated sleep-medication reports and cognitive decline in US and European over-50s
Adults over 50 reporting sleep-medication use showed slightly faster decline in cognition and memory in US and European cohorts.
Preprint · not peer-reviewed -
Health todayDementia refines
Visual, hearing and dual sensory impairment linked to higher dementia risk in UK Biobank
Measured visual, hearing and dual sensory impairment each predicted dementia after allowing for baseline cognition, in 51,584 UK Biobank adults.
Peer-reviewed -
Health todayDementia refines
COVID-19 and later cognitive impairment and dementia by vaccination status in England
Dementia diagnoses rose sharply in the month after COVID-19, and cognitive impairment stayed raised for up to 4 years.
Preprint · not peer-reviewed -
Health todayDementia new
Physical frailty and faster clinical decline on lecanemab in early Alzheimer's disease
In 187 patients starting lecanemab, physical frailty was linked to faster decline on the CDR-SB and more infusion-related reactions.
Peer-reviewed -
Data, models and systemsValue in health confirms
Lecanemab and donanemab for early Alzheimer's disease are not cost-effective in China
A lifetime Markov model found that neither lecanemab nor donanemab was cost-effective at current Chinese prices, from either perspective.
Peer-reviewed -
Health todayDementia refines
Cognition in healthy adults: modifiable risk factors linked to performance, not decline
Five modifiable dementia risk factors were linked to cognitive level, not decline, in 1,396 healthy adults aged 36 to 108.
Preprint · not peer-reviewed -
Health todayDementia refines
Eating difficulty marks functional vulnerability rather than triggering cognitive decline
In four ageing cohorts, new eating difficulty was associated with higher dementia-indicator risk, but tooth loss showed little adjusted association.
Peer-reviewed -
Data, models and systemsForecasts and their record new
Alzheimer's disease model links slower cognitive decline to later institutionalisation
In a memory clinic microsimulation, 30% slower MMSE decline delayed institutional care by 1.1 years, with similar time spent there.
Peer-reviewed -
Health todayDementia refines
Education and dementia: a schooling reform cut incidence and weakened genetic risk
A compulsory schooling reform showed that extra education lowered dementia incidence and weakened the link between genetic risk and dementia.
Peer-reviewed